TABLE 1

Patient Characteristics of Study Population

Patient no	Age (y)	Sex	Type MTC	CgA (mg/L)	Calcitonin (ng/L)	Calcitonin doubling time (mo)	CEA μg/L	CEA doubling time (mo)	CT or MRI	DMSA-V	¹⁸F-FDG PET	¹⁸F-F-DOPA PET	Imaging performance or histologic confirmation
1	71	M	spor	58	418	53	5.2	143	Neg	Neg	Neg	Neg	−/N
2^*	56	F	MEN 2a	32	10,500	8	414.8	9	Li5; os2	Neg	he1; li2; os2	li2; os2	−/N
3	66	M	spor	37	825	13	7.3	247	Neg	Neg	Neg	ab1	++
4	71	M	spor	466	120,000	24	2,209.5	29	Li8; os10	Neg	Neg	li10; os2	+
5	68	F	MEN 2a	200	27,190	91	1,459.5	151	Li10; os5	ne3; th1; li4;os1	Neg	he1; ne3; th1; li10; os1	+
6	48	M	MEN 2b	147	1,080	61	32.5	103	Neg	Neg	Neg	ne1	+/Y
7	56	M	MEN 2a	35	48	43	1.4	268	N/P	Neg	Neg	Neg	−/N
8	27	F	MEN 2a	23	73	29	1.2	77	Neg	os2	ne1	Neg	—/N
9	52	M	spor	77	173	34	14	−46	Neg	Neg	Neg	Neg	−/N
10	43	F	MEN 2a	28	86	76	1.1	−40	Neg	Neg	Neg	ab1	+/N
11	59	F	spor	56	1,596	−22	30.3	56	He1; ne2	N/P	N/P	he1; ne2	−/N
12^*	57	M	spor	910	109,000	8	647.1	15	He1; ne1; th10; li5	N/P	N/P	he1; ne2; th10; li8	+/Y
13	48	F	MEN 2a	82	112	−43	0.5	232	N/P	Neg	Neg	Neg	−/N
14	78	M	MEN 2a	147	2,812	27	3.4	−108	Ne1; th5	ne1	N/P	ne1; th3; li1	+/Y
15	34	F	spor	26	4,600	29	9.8	−42	Neg	N/P	N/P	ne1	+/Y
16	72	F	MEN 2a	120	19,350	68	194.3	−98	Neg	Neg	Neg	ne1; th1; li10	++
17	45	M	spor	284	1,049	108	29.5	50	Neg	h1	Neg	Neg	—/N
18^*	65	F	spor	55	1,160	4	41.9	7	he1; ne3; os10	Neg	ne4; th6; li7; os1	he1; ne3; th1; li5; os1	+
19	58	F	spor	1,090	24	23	0.6	22	Neg	Neg	Neg	Neg	−/N
20	26	F	spor	35	261	N/A	0.9	−24	Neg	Neg	Neg	Neg	−/N
21	79	M	spor	144	1,758	13	664.8	12	N/P	ne2; ab1	ne1; th3; li1; ab2	ne1; th2; li1; ab3	−/N

↵* Patients who died of their disease.
Patients in boldface type are patients with a short calcitonin doubling time.
Spor = sporadic medullary thyroid cancer; MEN = multiple endocrine neoplasia; CgA = chromogranin A, reference level < 100 ug/L; calcitonin reference level < 12 ng/L; CEA = carcinoembryogenic antigen, reference level < 5 ug/L; Neg = negative; N/P = not performed; N/A = not applicable.
Imaging regions: he = head; ne = neck; th = thorax; li = liver; ab = abdomen; os = ossal. The number after the region denotes the number of lesions for that region.
Imaging performance: − = no added value to conventional; + = more lesions detected; ++ = ¹⁸F-DOPA PET only positive imaging modality; — = ¹⁸F-DOPA PET inferior; Y =imaging results have been cytologically confirmed; N = no histologic or cytologic confirmation has been made.